Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 27, 2020

EKF Diagnostics to double PrimeStore device production amid Covid-19

EKF Diagnostics is planning to ramp up the production of the US Food and Drug Administration (FDA)-approved PrimeStore MTM device due to an increase in global demand amid Covid-19 pandemic outbreak.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.


EKF Diagnostics is planning to ramp up the production of the US Food and Drug Administration (FDA)-approved PrimeStore MTM device due to an increase in global demand amid Covid-19 pandemic outbreak.

The sample collection device enables safe handling and transport by deactivating viruses, bacteria, fungi and mycobacterium tuberculosis.

It has been designed to rapidly de-activate pathogen and stabilise RNA for up to four weeks with no requirement for cold storage.

The approach is said to reduce the risk of infection while allowing the samples to be tested by a higher number of laboratories.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

EKF has been rapidly increasing the production to meet the demand of one of the key components in PrimeStore MTM, which is manufactured at the company’s site in Boerne, Texas, US.

The company fulfilled the initial purchase orders worth $1m last month.

Currently, EKF anticipates additional orders worth $3m from Longhorn Vaccines and Diagnostics next month.

The company noted that the majority of the orders will be for the core reagent used within the device. It is in the process of doubling its manufacturing capacity for the reagent to fulfil these and anticipated future orders.

EKF also reported a decrease in the sales of its core diabetes and haemoglobin products in recent weeks due to lockdown measures. However, the increased contribution from the Longhorn manufacturing contract is expected to help the company exceed the overall management budgets for the first half of the year.

EKF said in a statement: “The Board also remains confident of exceeding its expectations for the full year. However, the quantum of this positive trading performance will only be known with certainty as the year progresses and further guidance will be provided later in the year.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU